<DOC>
	<DOCNO>NCT01984242</DOCNO>
	<brief_summary>This multicenter , randomize , open-label study evaluate efficacy , safety tolerability atezolizumab monotherapy combination bevacizumab versus sunitinib participant histologically confirm , previously untreated locally advanced metastatic renal cell carcinoma receive prior systemic therapy either adjuvant metastatic setting .</brief_summary>
	<brief_title>A Phase 2 Study Atezolizumab ( Engineered Anti-Programmed Death-Ligand 1 PD-L1 Antibody ) Monotherapy Combination With Bevacizumab ( Avastin® ) Compared Sunitinib ( Sutent® ) Participants With Untreated Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Unresectable advance metastatic renal cell carcinoma component clear cell histology and/or component sarcomatoid histology previously treat systemic agent , include treatment adjuvant set Measurable disease , define RECIST v1.1 Karnofsky performance score great equal ( &gt; /= ) 70 Adequate hematologic endorgan function define protocol Women childbearing potential male participant partner childbearing potential must agree use highly effective method contraception define protocol DiseaseSpecific Exclusions : Radiotherapy renal cell carcinoma within 14 day prior Cycle 1 , Day 1 exception : Singlefraction radiotherapy give indication pain control Known active malignancy metastasis brain spinal cord leptomeningeal disease , determine compute tomography ( CT ) magnetic resonance imaging ( MRI ) evaluation screen prior radiographic assessment Uncontrolled pleural effusion , pericardial effusion , ascites require recurrent drainage procedure ( monthly frequently ) Uncontrolled hypercalcemia symptomatic hypercalcemia Malignancies renal cell carcinoma within 5 year prior Cycle 1 , Day 1 , exception negligible risk metastasis death , treat expect curative outcome General Medical Exclusions : Life expectancy le ( &lt; ) 12 week Pregnant lactating woman History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein History autoimmune disease History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest CT scan Participants active chronic hepatitis B , active hepatitis C , Human Immunodeficiency Virus ( HIV ) positive test , significant cardiovascular disease Prior allogeneic stem cell solid organ transplant Exclusion Criteria Related Medications : Prior treatment Cluster Differentiation 137 ( CD137 ) agonists , antiCytotoxic TLymphocyte Antigen4 ( CTLA4 ) , antiPD1 , anti PDL1 therapeutic antibody pathwaytargeting agent Treatment systemic immunostimulatory agent reason within 6 week five halflives drug , whichever short , prior Cycle 1 , Day 1 Treatment systemic immunosuppressive medication within 2 week prior Cycle 1 , Day 1 Bevacizumab SunitinibSpecific Exclusions : Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association Class II great congestive heart failure History myocardial infarction unstable angina , stroke transient ischemic attack within 3 month prior Cycle 1 , Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>